The Efficacy and Safety of Anlotinib Treatment for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Who Achieved Stable Disease (SD) After Two Cycles of First-Line Chemotherapy Combined with Immunotherapy: A Retrospective Cohort Study
Adaptive use of Anlotinib could be a safe and effective option in advanced NSCLC patients who achieved SD after two cycles of first-line CIO. This regimen is expected to become an important option for precision and personalized treatment of NSCLC. However, due to the limitations of retrospective nature, its clinical value needs to be further confirmed by prospective studies.
Authors
- Yunhao Liu (ORCID: https://orcid.org/0009-0000-8844-1270)
- Xiaobing Li (ORCID: https://orcid.org/0000-0002-3332-0575)
- Jing Tang (ORCID: https://orcid.org/0000-0003-1013-147X)
- Kai‐Yan Liu (ORCID: https://orcid.org/0000-0002-6751-7827)
- Xi Lin (ORCID: https://orcid.org/0000-0003-3911-9677)
- Yi Peng (ORCID: https://orcid.org/0000-0001-7830-4694)
- De Pei Wu
Institutions
- Zhejiang Provincial People's Hospital (CN)
- Hubei Cancer Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Cancer Management and Research
- Published
- 2025-11-01
- DOI
- https://doi.org/10.2147/cmar.s539781
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Hubei Province